Tigecycline is one of the last-resort antibiotics to treat complicated infections caused by both multidrug-resistant Gramnegative and Gram-positive bacteria 1 . Tigecycline resistance has sporadically occurred in recent years, primarily due to chromosome-encoding mechanisms, such as overexpression of efflux pumps and ribosome protection 2, 3 . Here, we report the emergence of the plasmid-mediated mobile tigecycline resistance mechanism Tet(X4) in Escherichia coli isolates from China, which is capable of degrading all tetracyclines, including tigecycline and the US FDA newly approved eravacycline. The tet(X4)-harbouring IncQ1 plasmid is highly transferable, and can be successfully mobilized and stabilized in recipient clinical and laboratory strains of Enterobacteriaceae bacteria. It is noteworthy that tet(X4)-positive E. coli strains, including isolates co-harbouring mcr-1, have been widely detected in pigs, chickens, soil and dust samples in China. In vivo murine models demonstrated that the presence of Tet(X4) led to tigecycline treatment failure. Consequently, the emergence of plasmidmediated Tet(X4) challenges the clinical efficacy of the entire family of tetracycline antibiotics. Importantly, our study raises concern that the plasmid-mediated tigecycline resistance may further spread into various ecological niches and into clinical high-risk pathogens. Collective efforts are in urgent need to preserve the potency of these essential antibiotics.
The emergence and spread of antimicrobial resistance in Enterobacteriaceae bacteria pose a serious threat to human and animal health. Of special concern is the emerging resistance to carbapenems, as these agents are often regarded as the last line of effective therapy for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria 4 . Antibiotic treatment options for carbapenem-resistant Enterobacteriaceae (CRE) bacteria are becoming limited, and colistin and tigecycline have been regarded as the final armamentarium 5 . However, the recent discovery of a plasmid-mediated colistin resistance gene, mcr-1, threatens the clinical utility of colistin to treat these infections, leaving tigecycline as one of the last options 6 . Tigecycline resistance has inevitably emerged over the recent years, mostly identified among extensively drug-resistant and carbapenem-resistant isolates 7, 8 . Decreased susceptibility to tigecycline is commonly associated with overexpression of efflux pumps of the resistance-nodulation cell division protein family, such as AcrABTolC, OqxAB and AdeABC [9] [10] [11] . Meanwhile, mutations in plsC, rpsJ, trm, tet(A) and tet(M) have also been found to decrease tigecycline susceptibility [12] [13] [14] [15] [16] . By contrast, tetracycline destructases, such as Tet(X), represent a unique enzymatic tetracycline inactivation mechanism 17 . Tet(X), the flagship tetracycline-inactivating enzyme 18 , has been confirmed for in vitro activity in degrading all tetracyclines, including tigecycline 19 . Since being first described in the obligate anaerobe Bacteroides fragilis, tet(X) and its orthologous genes (namely, tet(X1) and tet(X2)) have now been detected in clinical Enterobacteriaceae and Acinetobacter baumannii isolates, but their distribution, genetic structure and clinical significance remain to be explored 20, 21 . In this study, we describe a plasmid-mediated mobile tigecycline resistance gene, tet(X4), and explore the prevalence of tet(X4)-positive Escherichia coli strains in humans, food-producing animals and the surrounding environment in China (Fig. 1) .
Initially, a tigecycline-resistant E. coli strain LHM10-1 (8 mg l −1 ; Supplementary Table 1) was isolated from the stool sample in an intensive pig farm (Jiangxi, China) in July 2017. The tigecycline resistance could be successfully transferred into the recipient E. coli C600 (8 mg l −1 ; Supplementary Table 1 ), suggesting that the gene encoding tigecycline resistance might be plasmid-borne. Whole-genome sequencing of E. coli LHM10-1 showed that it belonged to sequence type (ST) 515, and contained one 4.81-Mb chromosome and six plasmids with sizes of 108,366 bp (pLHM10-1-p1, IncF), 98,254 bp (pLHM10-1-p2, untypeable), 33,301 bp (pLHM10-1-p3, IncX4), 28,942 bp (pLHM10-1-p4, untypeable), 28,519 bp (pLHM10-1-p5, untypeable) and 12,783 bp (pLHM10-1-p6, IncQ1).
A tet(X)-like gene (designated as tet(X4)), with 1,158 bp in length, was found to be located on the IncQ1 plasmid pLHM10-1-p6. The tet(X4) gene encoded a 385 amino acid protein ( Fig. 2a and Supplementary Fig. 1a) , which showed 94.5% amino acid Letters Nature Microbiology sequence identity to Tet(X), initially found in the obligate anaerobe B. fragilis (GenBank accession number M37699). Meanwhile, Tet(X4) displayed 63.9%, 95.1% and 85.7% identities to the other named Tet(X) orthologues Tet(X1) (AJ311171), Tet(X2) (AJ311171) and Tet(X3) (AB097942), respectively ( Supplementary Fig. 1a) .
Gene cloning experiment showed that the tet(X4) construct, namely, E. coli JM109 + pBAD24-tet(X4), demonstrated a 64-fold increase in the minimum inhibitory concentration (MIC) of tigecycline when compared with the host E. coli JM109 strain carrying pBAD24 (0.25 mg l −1 ; Supplementary Table 1) . Similarly, MICs of the first-generation and second-generation tetracyclines were increased at least 32-fold. In addition, the MIC of the US FDA newly approved eravacycline, which was structurally similar to tigecycline with two modifications at C7 and C9, increased 512-fold (4 mg l −1 ; Supplementary Table 1 ). In addition, the agar well diffusion assay showed that the addition of supernatant from E. coli JM109 + pBAD24-tet(X4) resulted in the elimination of the tetracycline inhibition zone, whereas there were no significant changes between the negative and blank controls, suggestive of inactivation of tetracyclines by Tet(X4) (Fig. 2b) . Furthermore, liquid chromatography-tandem mass spectrometry (LC-MS/MS) showed that the level of tetracycline remained (16.1 ± 1.2%) after incubation with E. coli JM109 + pBAD24-tet(X4) for 16 h (verse (80.2 ± 1.2%) in the negative control) ( Fig. 2c ; P < 0.0001), and eravacycline remained only (7.8 ± 0.5%) after incubation for the same time (verse (79.0 ± 3.8%) in the negative control) ( Fig. 2d ; P < 0.0001). Our above results demonstrated that Tet(X4) was able to confer resistance to the entire family of tetracyclines.
In E. coli LHM10-1, the tet(X4)-harbouring plasmid pLHM10-1-p6 was 12,783 bp in size with an average G + C content of 55.4% and contained 15 predicted open reading frames (ORFs), of which tet(X4) was adjacent to two copies of ISCR2 (one is truncated; Fig. 3a) . Plasmid replicon analysis showed that pLHM10-1-p6 belonged to the broad host-range IncQ1 group, possessing the IncQ1 plasmid backbone genes for plasmid replication (repA, repB and repC) and mobilization (mobA, mobB and mobC). A comparison of several IncQ1 plasmids from the public National Center for Biotechnology Information (NCBI) database (https://www.ncbi. nlm.nih.gov/) demonstrated that they shared similar replication and mobilization regions, but diverse acquired regions (between repC and mobC) (Fig. 3b) . The results suggested that pLHM10-1-p6 originated by acquisition of tet(X4) into an IncQ1 plasmid, probably associated with the translocation of ISCR2.
Interestingly, a mcr-1-carrying IncX4 plasmid pLHM10-1-p3 (33,301 bp) was identified in the same E. coli LHM10-1, which shared >99% sequence identity and 100% query coverage to several other mcr-1-harbouring plasmids (for example, KX084392 and CP018773) from animal and human sources in China, the United States and some other countries. In addition, an extended-spectrum β-lactamase gene bla CTX-M-14 was identified on the chromosome of E. coli LHM10-1.
Further conjugation assays showed that tigecycline resistance could be successfully transferred from E. coli LHM10-1 into laboratory strains E. coli C600, Salmonella enterica serovar Typhimurium American Type Culture Collection (ATCC) 14028 and Klebsiella pneumoniae ATCC 700603, at a frequency of (1.2 ± 0.5) × 10 −2 , (1.2 ± 0.3) × 10 −4 and (6.2 ± 1.3) × 10 −2 cells per recipient cell, respectively (Fig. 3c) . Notably, pLHM10-1-p6 also exhibited good transferability into clinical CRE strains, including NDM-5-producing ST167 E. coli 1314 and KPC-2-producing ST11 K. pneumoniae 1332, at a frequency of (2.2 ± 0.5) × 10 −4 and (8.0 ± 0.5) × 10 −6 , respectively (Fig. 3c) . MICs of tetracyclines, including tigecycline and eravacycline, among these transconjugants, were increased at least four-fold (Supplementary Table 1 Table 2 ). These tet(X4)-positive E. coli isolates were found in five provinces in southern and eastern China ( Fig. 1) : Guangdong (n = 12), Fujian (n = 11), Jiangsu (n = 8), Jiangxi (n = 6) and Guangxi (n = 5). However, the tet(X4)-positive E. coli strains were not detected in others.
Although we have not identified tet(X4)-positive E. coli strains from human sources, a series of bacterial genomes carrying tet(X4)-like genes from human (for example, CP023968), animal (for example, CP002562), water (for example, CP023049) and soil (for example, LT906465) sources were identified in the NCBI ( Supplementary  Fig. 1b) . Furthermore, the sequence analysis also indicated that the tet(X4)-like genes had spread outside China and into other countries, including the United States (for example, NZ_JYQO01000042), the United Kingdom (for example, CP000685) and Thailand (for example, NZ_JRQZ01000088) ( Supplementary Fig. 1b) .
The susceptibility testing demonstrated that the 42 tet(X4)-positive E. coli strains were all resistant to tigecycline, tetracycline, sulfamethoxazole-trimethoprim and florfenicol, while 15 (35.7%), 12 (28.6%), 10 (23.8%), and 9 (21.4%) isolates showed resistance to ciprofloxacin, cefotaxime, gentamicin and colistin, respectively (Fig. 4) . In addition, all isolates exhibited an eravacycline MIC of 4-8 mg l ) for E. coli strains from the routine surveillance 22 . Notably, the 12 cefotaxime-resistant isolates were all found to carry extended-spectrum β-lactamase genes, including bla CTX-M-14 (n = 7), bla CTX-M-65 (n = 4) and bla CTX-M-27 (n = 1). The nine colistin-resistant E. coli strains all carried the colistin resistance gene mcr-1 and the extended-spectrum β-lactamase gene bla CTX-M (bla CTX-M-14 or bla CTX-M-65 ), belonging to two STs (ST515 (n = 5) and ST1196 (n = 4)). 
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Multilocus sequence typing showed that the 42 tet(X4)-positive E. coli strains belonged to nine distinct STs, which were, in general, consistent with the pulsotypes (A-K) from the pulsed field gel electrophoresis (PFGE) analysis (Fig. 4) . Strains from the same ST or PFGE pulsotype usually shared similar antimicrobial resistance profiles. Two STs (ST8302 and ST8338) were first identified in the current study, with ST8302 being the most predominant ST (n = 16; 38.1%) overall. Notably, the same STs of strains (ST8302, ST515, ST761 and ST10) in this study were identified in different geological regions and sources, suggesting the possibility of clonal spread of the same tet(X4)-positive strains across different regions.
The detection of the IncQ1 pLHM10-1-p6-like plasmid revealed that 57.1% (24 out of 42) of the tet(X4)-positive E. coli isolates harboured the same pLHM10-1-p6-like plasmid (Fig. 4) . These strains belonged to 4 distinct STs (ST8302 (n = 16), ST515 (n = 6), ST761
(n = 1) and ST871 (n = 1)) and were isolated from 4 different provinces (Guangdong (n = 7), Jiangsu (n = 7), Jiangxi (n = 6) and Fujian (n = 4)). Most of them were collected from pigs (n = 14) and chickens (n = 7), followed by dusts (n = 2) and soils (n = 1).
Notably, IncQ-type plasmids are a group of relatively small (approximately 5-15 kb), non-conjugative but mobilizable plasmids that can be transferred into a broad range of bacterial hosts in the presence of self-transmissible helper plasmids 23 . Our mating experiment results showed that pLHM10-1-p6 could be successfully transferred in the presence of the mcr-1-carrying IncX4 plasmid pZ6-2 (transfer frequency:
), the IncI2 plasmid pHLJ179 (transfer frequency: (7.9 ± 1.5) × 10 Letters Nature Microbiology along with pLHM10-1-p6 into the recipient E. coli C600 was not observed under the selection by tigecycline. Our results indicated that a helper plasmid is needed for the mobilization of tet(X4)-harbouring pLHM10-1-p6-like plasmids, and importantly, common mcr-1-bearing plasmids may serve as helper plasmids to further facilitate the spread of plasmid-mediated tigecycline resistance.
Moreover, whole-genome sequencing of another colistin-resistant ST1196 strain, E. coli G3X16-2, showed that it consisted of one Supplementary Fig. 2 ), which suggested that the tigecycline resistance may be co-selected by other antimicrobial resistances. Intriguingly, pG3X16-2-p2 harboured four tandem repeated ISCR2-catD-tet(X4)-ISCR2 gene cassettes on the same plasmid, suggesting that the tet(X4)-harbouring genetic elements are highly active and may further transfer to other plasmids or chromosome.
Results of the in vivo experiment showed that the mice infected with the plasmid-cured isogeneic strain E. coli STB20-1S (tet(X4) negative) were highly susceptible to tigecycline treatment, with more than 2 log 10 (colony-forming unit (c.f.u.) per gram) reduction in E. coli counts (P < 0.0001), whereas tigecycline had no significant effect on animals infected by E. coli STB20-1 after 24 h of treatment (Fig. 2e) . The results indicated that the presence of tet(X4) may contribute to tigecycline treatment failure.
In this study, the tet(X4)-positive E. coli strains were identified in pigs, chickens and their surrounding environmental samples from different geographical regions, indicating that Tet(X4)-encoding tigecycline resistance might have already spread in China. We suspected that the usage of 'older' generations of tetracyclines had largely contributed to the emergence of newer mobile tigecycline resistance. In China, tigecycline is only approved for the treatment of clinical infections in humans, whereas its usage in food-producing animals is not authorized. However, the first-generation and second-generation tetracyclines were widely used in the treatment of infections in food-producing animals and for growth promotion at sub-therapeutic doses in China, probably providing a selective pressure for the emergence of tigecycline resistance 24 . As one of the countries with the largest amount of antibiotics usage in the world, 12,000 tons (7.4%) of tetracyclines were consumed by China yearly (data from 2013), and most of them eventually entered into environment 25 . Similarly in Europe, although the European Union had phased out the use of antibiotics as growth promoters, the latest European Centre for Disease Prevention and Control-European Food Safety Authority-European Medicines Agency joint report (2017) on the integrated analysis of antibiotic consumption and antimicrobial resistance in bacteria revealed that tetracyclines were still the most sold antibiotics in Europe, and a statistically significant positive association between tetracycline consumption and resistance in E. coli strains was observed in food-producing animals 26 . Of concern, the selective pressure imposed by the continuous application of tetracyclines in veterinary practice could serve to maintain and spread the tet(X4)-like genes into pathogenic microorganisms.
The mobile antimicrobial resistance mechanisms, including Tet(X4), MCR and different families of carbapenemase (for example, NDM), represent a plasmid-mediated antibiotic crisis. However, the reality is that only limited antibiotics on the market or in the pipeline are effective against these highly resistant organisms. Continuous selection pressure from the environment, veterinary usage and clinical practice will probably accelerate the spread of tet(X4) and other resistance genes. The horizontal transfer ability of the resistance genes and plasmids, such as the tet(X4)-harbouring broad host range IncQ1 plasmid, can be a challenge for hospital infection control and public health surveillance. Our study underscores the need for a 'one-health' strategy (that is, considering the span of humans, animals and their environment) for antimicrobial resistance, as infectious disease surveillance and containment across different sectors are paramount. To make this last-resort drug available, the prevalence of tet(X4) in both human and veterinary fields should be considered by surveillance programmes, along with judicious administration of tetracyclines in animals and the environment.
Methods
Sample collection and bacterial strains. This study was approved by the institutional review board of hospital A (Huizhou Municipal Central Hospital) and South China Agricultural University (SCAU). The clinical isolates from hospitals B, C and D were retrospectively collected, and patient data were not included in this study; thus, ethical approval was not sought and obtained. The faecal samples were randomly collected from pigs (3-8 months of age) and chickens (7-20 weeks of age), with approximately 50 samples per farm. If possible, the soil, dust, sewage and vegetable samples were also collected, at least three samples per farm.
To examine the spread of mobile tigecycline resistance gene tet(X4), samples and clinical isolates were screened from 4 tertiary-care hospitals and 63 intensive animal farms (pig farms, n = 41; chicken houses, n = 22) in 16 provinces or municipalities in China (Fig. 1) . The four hospitals are located in Guangdong (hospitals A and B), Jiangsu (hospital C) and Zhejiang (hospital D) provinces. The pig farms and chicken houses are distributed in four geographical regions of China (Northeast, Southeast, West and Central China) and cover most livestock breeding areas in China. Briefly, a total of 4,189 samples from the animal sector were collected from May 2015 to May 2018 (Supplementary Table 2 ) and subjected to selection on MAC plates containing tigecycline (2 mg l
−1
). The selected tigecyclinenon-susceptible isolates were then subjected to tet(X4) screening. In addition, 299 human specimens from hospital A collected in the same period and a random collection of 720 E. coli clinical isolates from hospitals B, C and D were also screened as described above (Supplementary Table 2) .
Porcine E. coli LHM10-1 was selected as the donor strain, while laboratory strains (E. coli C600 (streptomycin resistance), S. Typhimurium ATCC 14028 (rifampin resistance), and K. pneumoniae ATCC 700603 (rifampin resistance)) and clinical MDR strains (E. coli 1314 carrying bla NDM-5 (ST167) and K. pneumoniae 1332 carrying bla KPC-2 (ST11)) were chosen as recipient strains for conjugation and plasmid stability tests. Porcine E. coli STB20-1 carrying a single plasmid (tet(X4) positive) was selected for the in vivo infection model.
Whole-genome sequencing. Genomic DNA was extracted from E. coli LHM10-1 using a TIANamp Bacteria DNA Kit (Tiangen), followed by genomic DNA sequencing with a MiSeq platform (Huayin Health). To obtain the complete plasmid sequences, E. coli LHM10-1 was also subjected to single-molecule realtime sequencing with a PacBio RSII system (Nextomics). In addition, another tet(X4)-positive E. coli strain, G3X16-2, was completely sequenced using a combined Illumina HiSeq and Nanopore sequencing approach (Nextomics). Genome assembly was performed with Unicycler version 0.4.1 (ref. 27 ) using a combination of short and long reads, followed by error correction by Pilon version 1.12 (ref. 28 ). The functional genes were annotated and classified using the RAST server 29 . The sequence types and plasmid replicon types were analysed by the CGE server (https://cge.cbs.dtu.dk/services/). Visual representation of the genetic structure of tet(X4)-carrying plasmids was generated with DNAPlotter version 1.11 (ref. 30 ).
Subcloning experiments.
To confirm the role of Tet(X4) in tigecycline resistance, the full-length ORF of tet(X4) was amplified from genomic DNA of E. coli LHM10-1 with the addition of an EcoRI restriction site at the 5′ end and a SalI restriction site at the 3′ end (Supplementary Table 4 ). Both the purified PCR product and the plasmid vector pBAD24, containing the arabinose pBAD promoter, were digested with restriction endonucleases EcoRI/SalI and then ligated at 16 °C overnight following the manufacturer's instructions (New England Biolabs). Subsequently, the recombinant plasmid pBAD24-tet(X4) was transformed into competent E. coli JM109 by heat shock and then subjected to susceptibility testing against different tetracyclines using a broth microdilution method.
Microbiological degradation assays.
The activities of Tet(X4) on tetracycline antibiotics degradation were initially assessed by an agar well diffusion method 31 . First, a suspension of the E. coli construct JM109 + pBAD24-tet(X4) was made by suspending the culture from a MH agar plate in 500 μl MH broth containing 0.1% l-arabinose (adjusted optical density at 600 nm of 2.0). The suspension was then inoculated with tetracycline (10 mg l ), and cultured at 37 °C for 8 h. Meanwhile, 100 µl of the overnight culture (0.5 McFarland) of Bacillus stearothermophilus 7953 (tetracycline susceptible) was spread on a MH agar plate surface. A hole with a 6-mm diameter was punched aseptically with a disposable hole puncher, and its bottom was sealed by a drop of heated liquid MH agar. Following centrifugation and filtration with a 0.22-μm filter, 20 µl of the supernatant from the JM109 + pBAD24-tet(X4) co-culture with different tetracycline antibiotics was added into the prepared agar hole and the plate was incubated at 60 °C for 16 h to examine the zone of inhibition. The E. coli JM109 + pBAD24 strain was used as a negative control, and the medium containing only tetracyclines acted as the blank control.
Quantifying the levels of tetracyclines via LC-MS/MS.
To further examine whether Tet(X4) was able to inactivate tetracyclines, the levels of tetracycline and eravacycline (tigecycline was not used because of its poor stability in growth media, even with the protection of 0.6 g l −1 ascorbic acid as previously described 32 ) were quantified in growth media of E. coli JM109 + pBAD24-tet(X4) by LC-MS/ MS in sextuplicate 17 . For tetracycline quantification, E. coli JM109 + pBAD24-tet(X4) was grown in 4 ml of M9 minimal media (1× M9 minimal salts, 2 mM MgSO 4 and 100 μM CaCl 2 ) containing 0.1% l-arabinose supplemented with 9 g l −1
glucose, 100 mg l −1 thiamine, 100 mg l −1 leucine and 8 mg l −1 tetracycline. The strain was incubated at 37 °C with shaking at 200 r.p.m. and protected from light for 16 h. Subsequently, cells were pelleted and the supernatant was passed through a 0.22-μm filter. The filtered supernatant was then diluted tenfold and subjected to LC-MS/MS quantification. Similarly, the level of eravacycline degradation was also determined by incubation with eravacycline (2 mg l −1
) for 16 h. The E. coli JM109 + pBAD24 strain was used as a negative control. The linear ranges of standard curves for tetracycline and eravacycline quantification were 25-800 ppb and 10-200 ppb, respectively, with r 2 > 0.995.
Mating experiments and plasmid stability testing. The transferability of tet(X4) in E. coli LHM10-1 was determined by filter mating using E. coli C600, S. Typhimurium ATCC 14028, K. pneumoniae ATCC 700603, E. coli 1314 and K. pneumoniae 1332 as recipient strains. Briefly, the donor and recipient strains were grown at log-phase in LB broth, and were then mixed at the donor/recipient ratio of 1/3 and applied to a 0.22-µm filter, followed by culture at 37 °C for 16 h. The putative transconjugants were selected as follows. For E. coli C600 and S. Typhimurium ATCC 14028, they were selected by MAC plates containing tigecycline (4 mg l Table 4 ). Transfer efficiency was calculated based on colony counts of the transconjugant and recipient cells in triplicate as previously reported 33 . Subsequently, the host E. coli LHM10-1 strain and its transconjugants were subjected to plasmid stability testing as previously described 34 . Briefly, three independent lineages of them were cultured overnight at 37 °C in 4 ml antibioticfree LB broth. Serial passaging of 4 µl of the overnight culture to 4 ml LB broth was performed daily, yielding approximately 10 generations of growth per passage. For every 20 generations, samples were diluted and plated on LB agar plates. Then, 50 colonies from each lineage were screened on LB agar plates with or without tigecycline (4 mg l −1 ) to determine the fraction of plasmid-containing cells. Tigecycline (8 µg ml ) was used for the transconjugant generated with K. pneumoniae ATCC 700603. The loss of plasmids was confirmed by the tet(X4) target PCR and ERIC-PCR as mentioned above.
In addition, the mobilizing efficiency of different helper plasmids on the IncQ1 plasmid pLHM10-1-p6 was determined by filter mating in triplicate. First, donor strains containing pLHM10-1-p6 and a single putative helper plasmid were constructed. In brief, the IncQ1 plasmid pLHM10-1-p6 was transferred into E. coli DH5α by heat shock and the putative transformant (namely, E. coli DH5α + pLHM10-1-p6) was selected by LB agar plates containing 4 mg l −1 tigecycline. Then, three laboratory E. coli strains, Z6-2, H12-4 and HLJ179, which have been confirmed to carry mcr-1-positive lncX4, lncFII and I2 plasmids, respectively, were used for filter mating with the recipient strain E. coli DH5α + pLHM10-1-p6. The putative constructs were selected by LB agar plates containing tigecycline (4 mg l ). PCR-based replicon typing [35] [36] [37] , S1-digested PFGE 4 and ERIC-PCR were conducted to confirm that only a single mcr-1-harbouring helper plasmid was transferred into E. coli DH5α + pLHM10-1-p6. Second, the pLHM10-1-p6-harbouring E. coli DH5α strains with a single putative helper plasmid (namely, pZ6-2, pH12-4 or pHLJ179) were used as donors for conjugation, with E. coli C600 as the recipient strain, followed by selection of transconjugants with the LB agar plates containing tigecycline (4 mg l ). The putative transconjugants and mobilizing efficiency were further determined as described above, respectively.
Screening for the presence of tet(X4) and the tet(X4)-harbouring pLHM10-1-p6-like plasmid. All tigecycline-non-susceptible isolates were screened for tet(X4) by PCR, followed by Sanger sequencing. The pLHM10-1-p6-like plasmid was also screened by overlapping PCRs targeting four overlapping regions (IncQ-1 (ΔczcD-orf1-ΔISCR2-Δtet(X4)), IncQ-2 (Δtet(X4)-catD-ISCR2-Δorf2), IncQ-3 (Δorf2-mobC-mobA-mobB-repB-ΔrepF) and IncQ-4 (repF-repA-repC-Δsul2-czcD-Δorf1)) on pLHM10-1-p6 (Supplementary Fig. 3 ). All of the primers used are listed in the appendix (Supplementary Table 4 ).
Antimicrobial susceptibility testing. MICs of ten antibiotics (tetracycline, amikacin, gentamicin, meropenem, cefoxitin, cefotaxime, fosfomycin, ciprofloxacin, sulfamethoxazole-trimethoprim and florfenicol) for all tet(X4)-harbouring strains were determined by agar dilution and interpreted according to the Clinical & Laboratory Standards Institute guidelines. MICs of tigecycline, eravacycline and colistin were determined by broth microdilution. In particular, the breakpoint of tigecycline for E. coli strains was interpreted according to the FDA criteria (susceptible, ≤2 mg l ). E. coli ATCC 25922 served as a quality control strain for susceptibility testing.
Molecular typing.
All tet(X4)-positive E. coli strains were classified by XbaIdigested (Takara) PFGE according to the PulseNet protocol (http://www. pulsenetinternational.org/protocols/) using a CHEF Mapper System (Bio-Rad). PFGE patterns were compared using BioNumerics version 6.6 (Applied Maths Software) under appropriate optimization (1.5%) and tolerance (1.5%) settings, with a cut-off at 85% similarity to delineate PFGE clusters. Multilocus sequence typing was performed by the primers and protocol specified on the E. coli multilocus sequence typing database website (http://enterobase.warwick.ac.uk).
Murine thigh infection model. Female Institute of Cancer Research (ICR) mice (6-10 weeks of age; Guangdong Medical Lab Animal Center, Guangzhou, China) were used in this experiment. Mice were maintained in accordance with the National Standards for Laboratory Animals in China (GB 14925-2010). All animal studies were conducted in accordance with the SCAU Institutional Animal Welfare and Ethics guidelines. The animal use procedures were approved by the Animal Research Committees of SCAU. No specific statistical consideration was taken in determining the sample size for the animal experiments. Investigators were blinded as for group allocation when determining c.f.u. Meanwhile, we were able to cure the tet(X4)-carrying plasmid from wild-type E. coli STB20-1 (tet(X4) positive) using sodium dodecyl sulfate as previously described 10 , to create STB20-1S (tet(X4) negative); thus, any difference caused by treatment would be most likely due to the presence of the plasmid only.
Prior to infection, mice were rendered neutropenic by injecting two doses of cyclophosphamide intraperitoneally on 4 d (150 mg per kg) and 1 d (100 mg per kg). To study the effect of the tet(X4)-carrying plasmid on the efficacy of tigecycline, thigh infections were produced by injecting 0.1 ml suspensions of E. coli STB20-1 or its tet(X4)-cured STB20-1S strain at 10 6 c.f.u. per ml. At 2 h postinfection, the mice were subcutaneously administered a single dose of tigecycline at 50 mg per kg per 24 h, which was approximately equivalent to the dosing regimen in humans given as 50 mg per 12 h for 6 d 38, 39 . Mice were humanely euthanized at 24 h after treatment and thigh muscles were aseptically homogenized in 3 ml saline. After serial dilutions, suspensions were quantitatively cultured on antibiotic-free LB agar plates for c.f.u. enumeration.
Statistical analysis.
Descriptive analyses on percentage (together with standard deviation) and prevalence were performed using functions provided in Excel 2007 (Microsoft Software). All statistical analyses (unpaired t-test, two-tailed; two-way analysis of variance (ANOVA)) were performed with GraphPad Prism 5 (GraphPad Software).
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
No specific statistical consideration was taken in determining the sample size. The fecal samples were randomly collected from pigs and chickens, with approximately 50 samples per farm. If possible, the soil, dust, sewage, and vegetable samples were also collected at least three per farm. What's more, 1019 isolates from four tertiary care hospitals in three provinces, which had been detected with tet(X4) from animal sector in this study, were collected for cinical epidemiological study. For the murine thigh infection model, six mice per group were used.
Data exclusions No data were excluded.
Replication
Quantifying the levels of tetracycline and eravacycline via LC-MS/MS and the efficacy of Tet(X4) conferring resistance to tigecycline in murine thigh infection model were performed in sextuplicate. Plasmid transfer frequency and stability testings were conducted in triplicate for characteristics of the tet(X4)-harboring plasmid pLHM10-1-p6. All replications were successfully conducted.
Randomization All the samples were randomly collected. All the organisms and participants involved in this study were allocated into groups randomly.
Blinding
Investigators were blinded as for group allocation during data collection and analysis.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
The fecal samples were randomly collected from pigs (3 to 8 months old) and chickens (7 to 20 weeks old) in 16 provinces or municipalities in China. Female ICR mice (6-10 weeks old; Guangdong Medical Lab Animal Center, Guangzhou, China) were also used for in vivo experiments in this study.
Wild animals
The study did not involve wild animals.
